Phase 1 Study of MCP-3100 in Patients With Refractory or Relapsed Cancer
This is a dose escalation study. As subjects participating in the study tolerate a specific
dose level, the new subjects entering will be given a higher dose of the study drug.
Interventional
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label
Safety and Tolerability (Maximum Tolerated Dose)
After each cohort is enrolled .
Yes
Andrew Beelen, MD
Study Director
Myrexis Inc.
United States: Institutional Review Board
MPC-3100-001
NCT00920205
June 2009
June 2011
Name | Location |
---|---|
Fox Chase Cancer Center | Philadelphia, Pennsylvania 19111 |
Nevada Cancer Institute | Las Vegas, Nevada 89135 |
South Texas Accelerated Research Therapeutics | San Antonio, Texas 78229 |